Semaglutide
Semaglutide is a peptide therapeutic — a synthetic, long-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) — used to treat type 2 diabetes and obesity.
Semaglutide is a peptide therapeutic — a synthetic, long-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) — used to treat type 2 diabetes and obesity. It is a modified analogue of the endogenous incretin hormone glucagon-like peptide-1, engineered with substitutions that resist dipeptidyl peptidase-4 cleavage and a fatty acid side chain that binds albumin, extending its half-life enough to permit once-weekly subcutaneous injection or, in a separate formulation with an absorption enhancer, once-daily oral dosing. It is marketed as Ozempic and Wegovy (injectable) and Rybelsus (oral), and lower-cost versions have appeared in some markets. Within the GLP-1 receptor agonist class it sits alongside liraglutide and the dual GIP/GLP-1 receptor co-agonist tirzepatide, and is used in combination with or as an alternative to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin therapy, but not with dipeptidyl peptidase-4 inhibitors, whose incretin mechanism it already supersedes.
Activation of GLP-1R produces glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, and marked slowing of gastric emptying — the last with practical consequences for capsule endoscopy and periprocedural fasting, and the main source of the nausea, vomiting and constipation that dominate its side-effect profile and dictate slow dose escalation. Because GLP-1 receptors are also expressed in the hypothalamus, brainstem and reward circuitry, semaglutide acts through the gut-brain axis to reduce appetite and food intake, and its interaction with dopaminergic signaling underlies investigation in addiction medicine, including alcohol use disorder. Weight loss is substantial but conditional on continued treatment: most is regained after discontinuation, and a meaningful fraction of what is lost is lean mass. Rarer concerns include gallbladder disease, a contested pancreatitis signal, and rodent thyroid C-cell tumors that make medullary thyroid carcinoma a contraindication.
Receptor expression outside the pancreas and brain extends its reach further. GLP-1 receptors on hepatic sinusoidal endothelial cells have been implicated in weight-loss-independent hepatoprotection, supporting its role in metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease, while large outcome trials have established cardiovascular risk reduction in type 2 diabetes and, separately, in obesity without diabetes, and slowed progression of chronic kidney disease. Interest in neurodegenerative indications has now been tested and did not survive: the evoke and evoke+ phase 3 trials randomised 3808 people with amyloid-confirmed early Alzheimer's disease, spanning mild cognitive impairment and mild dementia, to oral semaglutide 14 mg or placebo, found no difference in Clinical Dementia Rating-Sum of Boxes at 104 weeks, and were discontinued for negative clinical outcome. That null result contrasts with preclinical amyloid models, which have yielded metabolic benefits and, in some studies, reductions in amyloid-beta pathology and improvements in cognition, and it stands against the observational cohorts that had reported lower dementia incidence under GLP-1 receptor agonists.
Where the papers sit
82 papers from the last 6 months study semaglutide directly · updated from PubMed 12 Nov 2026
Study type 13 clinical trials · 11 observational · 12 human data · 20 preclinical · 26 unclassified
Themes 4 themes · 1 new direction
-
GLP-1 Therapeutics and Delivery
GLP-1 therapy is expanding across type 2 diabetes, obesity, prevention, and longer-acting peptide design. Real-world studies repeatedly assess persistence, effectiveness, safety, and use in special settings such as adolescence, Ramadan, surgery, and antipsychotic-associated weight gain. Molecular work targets IDE-mediated degradation, GLP-1R stability, antibody engagement, and stapled peptide scaffolds. Oral formulations, financing, carbon footprint, and patient preferences increasingly shape how these therapies may be deployed.
32 papers · 39%
-
Obesity Treatment and Persistence
Obesity treatment is moving from trial efficacy toward durable, real-world weight loss and long-term care. Persistence, tolerability, access, cost, and patient satisfaction recur alongside comparisons with tirzepatide, cagrilintide, surgery, and lifestyle programs. Weight regain and cardiometabolic changes after semaglutide withdrawal remain central uncertainties. Oral, sublingual, digital-service, and post-bariatric approaches seek easier delivery and sustained use, while safety signals require confirmation.
21 papers · 25.6%
-
Diabetes and Cardiovascular Outcomes
Type 2 diabetes care is increasingly comparing semaglutide with SGLT2 inhibitors and testing their combination across glycaemic, cardiovascular, endothelial, and kidney outcomes. Real-world cohorts and comparative effectiveness studies focus on cardiovascular events, diabetic kidney disease, safety, and durability outside trials. Discontinuation, including in automated insulin delivery and type 1 diabetes, highlights uncertainty about maintaining glycaemic benefit. GIP add-on therapy, lower prices, prevention after gestational diabetes, and alternative delivery systems broaden the clinical agenda.
19 papers · 23.2%
-
MASH Fibrosis Treatment
MASH treatment is moving beyond weight loss toward fibrosis regression, cirrhosis prevention, and integrated cardiometabolic care. Semaglutide is evaluated against resmetirom and standard care through clinical outcomes, health utility, and cost-effectiveness analyses. The recurring question is whether GLP-1 benefits reflect weight reduction alone or also direct effects on inflammation and hepatic fibrosis. Combination strategies and improved pathology assessment remain open avenues, with findings spanning people with HIV and preclinical liver cancer models.
10 papers · 12.2%
Semaglutide becomes a substrate-defined template for engineering CNS-stable agonists
The IDE-mediated GLP-1 and semaglutide degradation study identified semaglutide as a substrate through which insulin-degrading enzyme regulates GLP-1 activity, then used the cleavage sites to create D-amino-acid-substituted semaglutide with prolonged plasma and central nervous system stability and sustained glucose lowering in mice 42647645Aug. This gives semaglutide a role beyond an administered GLP-1 receptor agonist—as a mechanistic probe and molecular template for designing long-acting, CNS-stable agonists.
Papers
The 82 papers from the last 6 months that study semaglutide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
GLP-1 Therapeutics and Delivery (32)
- Investigating GLP-1 sourcing preferences on social media and motivations for use: Survey with choice-based conjoint (CBC) exercise. PloS one · 4 Nov 2026 PMID 42981240
- Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction. European heart journal · 5 Oct 2026 PMID 42830666
- Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production. BMJ open · 24 Sept 2026 PMID 42785932
- Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes. Diabetes, obesity & metabolism · 22 Sept 2026 PMID 42768825
- Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules. International journal of pharmaceutics · 20 Sept 2026 PMID 42764083
- Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study. BMJ open · 17 Sept 2026 PMID 42754274
- Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats. Molecular metabolism · 3 Sept 2026 PMID 42692145
- IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists. Science advances · 26 Aug 2026 PMID 42647645
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation · 18 Aug 2026 PMID 42610271
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting. Journal of enzyme inhibition and medicinal chemistry · 11 Aug 2026 PMID 42578506
- Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
- Microfluidic-assisted formulation of hydrophobic ion pairing-Based solid lipid nanoparticles for semaglutide delivery. International journal of pharmaceutics · 8 Aug 2026 PMID 42570682
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. The lancet. Diabetes & endocrinology · 7 Aug 2026 PMID 42567173
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice. Endocrinology, diabetes & metabolism · 5 Aug 2026 PMID 42552642
- Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
- Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
- Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease. International journal of cardiology · 26 Jun 2026 PMID 42361988
- Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 Jun 2026 PMID 42349668
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity (Silver Spring, Md.) · 25 Jun 2026 PMID 42345739
- Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation. European heart journal. Cardiovascular pharmacotherapy · 23 Jun 2026 PMID 42334436
- Negative effects of semaglutide on bone in obese mice. Cell reports. Medicine · 18 Jun 2026 PMID 42314683
- Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. Scientific reports · 12 Jun 2026 PMID 42286047
- GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes research and clinical practice · 10 Jun 2026 PMID 42269776
- Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland. Diabetes, obesity & metabolism · 9 Jun 2026 PMID 42264960
- Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. Molecular metabolism · 2 Jun 2026 PMID 42229580
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. Proceedings of the National Academy of Sciences of the United States of America · 2 Jun 2026 PMID 42228536
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy. Bioconjugate chemistry · 30 May 2026 PMID 42216891
- Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis. Journal of robotic surgery · 29 May 2026 PMID 42213238
- ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166306
Obesity Treatment and Persistence (21)
- Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study. Diabetes, obesity & metabolism · 29 Oct 2026 PMID 42957437
- Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS. Endocrine · 29 Oct 2026 PMID 42955519
- Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance. Pharmacoepidemiology and drug safety · 27 Oct 2026 PMID 42946127
- Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series. Diabetes, obesity & metabolism · 25 Oct 2026 PMID 42928048
- The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment. Obesity (Silver Spring, Md.) · 8 Oct 2026 PMID 42844829
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction. Diabetes, obesity & metabolism · 15 Sept 2026 PMID 42736522
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes. Journal of controlled release : official journal of the Controlled Release Society · 24 Aug 2026 PMID 42636888
- Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components. Neuromolecular medicine · 20 Aug 2026 PMID 42622904
- Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways. International immunopharmacology · 11 Aug 2026 PMID 42580144
- Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial. The lancet. Diabetes & endocrinology · 10 Aug 2026 PMID 42575111
- Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol. PloS one · 27 Jul 2026 PMID 42507673
- Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 24 Jul 2026 PMID 42495930
- Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. Nature communications · 21 Jul 2026 PMID 42481504
- Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis. iScience · 17 Jun 2026 PMID 42305583
- Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations. Diabetes, obesity & metabolism · 15 Jun 2026 PMID 42297758
- Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study. BMC cardiovascular disorders · 28 May 2026 PMID 42210124
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism · 28 May 2026 PMID 42207966
- Functional Performance of Silk Nanoparticles for Oral Drug Delivery. ACS applied materials & interfaces · 27 May 2026 PMID 42198918
- Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany. Diabetes, obesity & metabolism · 26 May 2026 PMID 42186215
- Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study. Obesity surgery · 22 May 2026 PMID 42174244
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. BMJ open · 20 May 2026 PMID 42161545
Diabetes and Cardiovascular Outcomes (19)
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine · 9 Oct 2026 PMID 42854065
- Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 29 Sept 2026 PMID 42810438
- Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes therapy : research, treatment and education of diabetes and related disorders · 17 Sept 2026 PMID 42753116
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
- Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study. Diabetes, obesity & metabolism · 1 Sept 2026 PMID 42675550
- Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation. International journal of pharmaceutics · 30 Aug 2026 PMID 42669320
- Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. BMJ open · 23 Jul 2026 PMID 42493207
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access. Obesity (Silver Spring, Md.) · 12 Jul 2026 PMID 42437874
- Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Annals of internal medicine · 29 Jun 2026 PMID 42372278
- Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, obesity & metabolism · 28 Jun 2026 PMID 42365987
- Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 26 Jun 2026 PMID 42362054
- 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. The lancet. Diabetes & endocrinology · 17 Jun 2026 PMID 42309121
- Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology · 17 Jun 2026 PMID 42308439
- Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database. Diabetes, obesity & metabolism · 17 Jun 2026 PMID 42304551
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response. Diabetes therapy : research, treatment and education of diabetes and related disorders · 15 Jun 2026 PMID 42295649
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet (London, England) · 7 Jun 2026 PMID 42251856
- Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes. Diabetes research and clinical practice · 29 May 2026 PMID 42214559
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease. Pakistan journal of pharmaceutical sciences · 22 May 2026 PMID 42170981
MASH Fibrosis Treatment (10)
- Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model. PloS one · 18 Sept 2026 PMID 42758714
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE. JHEP reports : innovation in hepatology · 11 Aug 2026 PMID 42580587
- Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study. HIV medicine · 28 Jul 2026 PMID 42517548
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. PharmacoEconomics · 26 Jul 2026 PMID 42503575
- AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. Nature communications · 22 Jul 2026 PMID 42486853
- GLP-1 and MASH: When weight loss isn't the whole story. Cell metabolism · 7 Jul 2026 PMID 42413474
- Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, obesity & metabolism · 25 Jun 2026 PMID 42348222
- LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis. International journal of obesity (2005) · 22 Jun 2026 PMID 42332016
- Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation. Med (New York, N.Y.) · 12 Jun 2026 PMID 42285042
By study type
Clinical trials (13)
- Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study. BMJ open · 17 Sept 2026 PMID 42754274
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
- Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study. Diabetes, obesity & metabolism · 1 Sept 2026 PMID 42675550
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation · 18 Aug 2026 PMID 42610271
- Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial. The lancet. Diabetes & endocrinology · 10 Aug 2026 PMID 42575111
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. The lancet. Diabetes & endocrinology · 7 Aug 2026 PMID 42567173
- Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol. PloS one · 27 Jul 2026 PMID 42507673
- Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. BMJ open · 23 Jul 2026 PMID 42493207
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet (London, England) · 7 Jun 2026 PMID 42251856
- Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study. Obesity surgery · 22 May 2026 PMID 42174244
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease. Pakistan journal of pharmaceutical sciences · 22 May 2026 PMID 42170981
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. BMJ open · 20 May 2026 PMID 42161545
Observational studies and case reports (11)
- Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS. Endocrine · 29 Oct 2026 PMID 42955519
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine · 9 Oct 2026 PMID 42854065
- Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice. Endocrinology, diabetes & metabolism · 5 Aug 2026 PMID 42552642
- Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 24 Jul 2026 PMID 42495930
- Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
- From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease. International journal of cardiology · 26 Jun 2026 PMID 42361988
- 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. The lancet. Diabetes & endocrinology · 17 Jun 2026 PMID 42309121
- Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes. Diabetes research and clinical practice · 29 May 2026 PMID 42214559
- Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis. Journal of robotic surgery · 29 May 2026 PMID 42213238
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166306
Human data, design not indexed (12)
- Investigating GLP-1 sourcing preferences on social media and motivations for use: Survey with choice-based conjoint (CBC) exercise. PloS one · 4 Nov 2026 PMID 42981240
- Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance. Pharmacoepidemiology and drug safety · 27 Oct 2026 PMID 42946127
- The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment. Obesity (Silver Spring, Md.) · 8 Oct 2026 PMID 42844829
- Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production. BMJ open · 24 Sept 2026 PMID 42785932
- Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access. Obesity (Silver Spring, Md.) · 12 Jul 2026 PMID 42437874
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity (Silver Spring, Md.) · 25 Jun 2026 PMID 42345739
- Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation. European heart journal. Cardiovascular pharmacotherapy · 23 Jun 2026 PMID 42334436
- Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology · 17 Jun 2026 PMID 42308439
- GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes research and clinical practice · 10 Jun 2026 PMID 42269776
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism · 28 May 2026 PMID 42207966
- ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
Preclinical: animal, cell and lab studies (20)
- Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules. International journal of pharmaceutics · 20 Sept 2026 PMID 42764083
- Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model. PloS one · 18 Sept 2026 PMID 42758714
- Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats. Molecular metabolism · 3 Sept 2026 PMID 42692145
- Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation. International journal of pharmaceutics · 30 Aug 2026 PMID 42669320
- IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists. Science advances · 26 Aug 2026 PMID 42647645
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes. Journal of controlled release : official journal of the Controlled Release Society · 24 Aug 2026 PMID 42636888
- Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components. Neuromolecular medicine · 20 Aug 2026 PMID 42622904
- Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways. International immunopharmacology · 11 Aug 2026 PMID 42580144
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting. Journal of enzyme inhibition and medicinal chemistry · 11 Aug 2026 PMID 42578506
- AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. Nature communications · 22 Jul 2026 PMID 42486853
- Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. Nature communications · 21 Jul 2026 PMID 42481504
- Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 Jun 2026 PMID 42349668
- Negative effects of semaglutide on bone in obese mice. Cell reports. Medicine · 18 Jun 2026 PMID 42314683
- Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations. Diabetes, obesity & metabolism · 15 Jun 2026 PMID 42297758
- Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. Molecular metabolism · 2 Jun 2026 PMID 42229580
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. Proceedings of the National Academy of Sciences of the United States of America · 2 Jun 2026 PMID 42228536
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy. Bioconjugate chemistry · 30 May 2026 PMID 42216891
- Functional Performance of Silk Nanoparticles for Oral Drug Delivery. ACS applied materials & interfaces · 27 May 2026 PMID 42198918
Unclassified: not yet indexed with MeSH (26)
- Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study. Diabetes, obesity & metabolism · 29 Oct 2026 PMID 42957437
- Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series. Diabetes, obesity & metabolism · 25 Oct 2026 PMID 42928048
- Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction. European heart journal · 5 Oct 2026 PMID 42830666
- Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 29 Sept 2026 PMID 42810438
- Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes. Diabetes, obesity & metabolism · 22 Sept 2026 PMID 42768825
- Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes therapy : research, treatment and education of diabetes and related disorders · 17 Sept 2026 PMID 42753116
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction. Diabetes, obesity & metabolism · 15 Sept 2026 PMID 42736522
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
- EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE. JHEP reports : innovation in hepatology · 11 Aug 2026 PMID 42580587
- Microfluidic-assisted formulation of hydrophobic ion pairing-Based solid lipid nanoparticles for semaglutide delivery. International journal of pharmaceutics · 8 Aug 2026 PMID 42570682
- Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study. HIV medicine · 28 Jul 2026 PMID 42517548
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. PharmacoEconomics · 26 Jul 2026 PMID 42503575
- GLP-1 and MASH: When weight loss isn't the whole story. Cell metabolism · 7 Jul 2026 PMID 42413474
- Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Annals of internal medicine · 29 Jun 2026 PMID 42372278
- Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, obesity & metabolism · 28 Jun 2026 PMID 42365987
- Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 26 Jun 2026 PMID 42362054
- Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, obesity & metabolism · 25 Jun 2026 PMID 42348222
- LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis. International journal of obesity (2005) · 22 Jun 2026 PMID 42332016
- Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis. iScience · 17 Jun 2026 PMID 42305583
- Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database. Diabetes, obesity & metabolism · 17 Jun 2026 PMID 42304551
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response. Diabetes therapy : research, treatment and education of diabetes and related disorders · 15 Jun 2026 PMID 42295649
- Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. Scientific reports · 12 Jun 2026 PMID 42286047
- Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation. Med (New York, N.Y.) · 12 Jun 2026 PMID 42285042
- Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland. Diabetes, obesity & metabolism · 9 Jun 2026 PMID 42264960
- Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study. BMC cardiovascular disorders · 28 May 2026 PMID 42210124
- Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany. Diabetes, obesity & metabolism · 26 May 2026 PMID 42186215
Written from 82 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-09-26 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.